Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABAL.L Regulatory News (ABAL)

  • There is currently no data for ABAL

Pharmaceutical Contract Win

14 Jan 2009 07:00

RNS Number : 5695L
Imaginatik PLC
14 January 2009
 



14 January 2009

Imaginatik Plc

("Imaginatik" or the "Company")

Pharmaceutical Contract Win

Imaginatik plc (AIM: IMTK), a leading provider of cost reduction, process improvement and collaborative innovation software and processes, is pleased to announce it has secured an annual contract with one of the world's leading pharmaceutical companies.

The annual contract, for 5,000 seats, is further evidence of the Company's strong presence within the pharmaceutical industry with the new client joining the likes of Pfizer, Merck, Novartis and Solvay on Imaginatik's client list. Imaginatik now provides its collaborative software to six of the world's top pharmaceutical companies, assisting those companies in harnessing the knowledge of their thousands of employees to identify potential new products, areas of cost-reduction and process enhancements. 

Under the terms of the contract, Imaginatik will be implementing its core product, Idea Central, across a number of divisions within the client, including Research, Prescription Medicine and IT. Idea Central will play a key role in delivering process and product improvement within these divisions.

A spokesperson for the client commented, "In furthering our emphasis on Value through Innovation, Imaginatik's Idea Central provided a focal point for idea generation and sharing, streamlined our reviewing process, and served as a vehicle for ongoing communication. We found Imaginatik's software and services to be particularly effective."

Mark Turrell, CEO of Imaginatik plc commented, "We are delighted to see the investment placed on strengthening our sales team being rewarded with significant annual contract wins which add to our increasingly impressive recurring revenue figure. This contract also once again demonstrates the value of our collaborative software to the pharmaceutical industry and we are confident that this will continue to be an excellent vertical for Imaginatik going forward."

For further information please contact:

Imaginatik plc

Tel: 020 7917 2975

Mark Turrell, CEO / Shawn Taylor, CFO

WH Ireland Limited

Tel: 0121 265 6330

Tim Cofman / Katy Birkin

ICIS

Tel: 020 7651 8688

Caroline Evans-Jones / Mike Smith

About Imaginatik

Imaginatik is the leading provider of cost reduction, process improvement and collaborative innovation software and processes to the world's leading companies. More than 100 clients rely on Imaginatik's software, consulting and research to enable their best-of-breed innovation activities.

Named as a World Economic Forum Technology Pioneer for 2008 and a finalist for the IBM Lotus Awards 2008 in the Best Industry Solution category, Imaginatik's software and consulting services have helped clients discover significant sources of additional revenue, as well as tangible cost savings, process improvements and increased product pipeline. Imaginatik is also committed to developing strategic solutions in the field of innovation, working with academic institutions such as the London Business School and the Cass School of Business, London, as well as leading practitioners of corporate innovation.

For further information please visit www.imaginatik.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUOOVRKORAAAR
Date   Source Headline
25th Jan 201211:30 amRNSHolding(s) in Company
23rd Jan 20127:01 amRNSContract Renewals worth £1.1m
3rd Jan 20127:00 amRNSDirectorate Change
22nd Dec 20117:00 amRNSContract extension
14th Dec 20117:00 amRNSLitigation Update
12th Dec 20117:00 amRNSContract Win
28th Nov 20117:00 amRNSHalf Yearly Report
28th Oct 20112:13 pmRNSChange of Adviser
28th Oct 201110:02 amRNSHolding(s) in Company
27th Oct 201110:45 amRNSHolding(s) in Company
13th Oct 20117:00 amRNSContract Extension
3rd Oct 201112:28 pmRNSDirectorate Change
26th Sep 20115:12 pmRNSResult of AGM
15th Sep 201110:24 amRNSHolding(s) in Company
2nd Sep 20113:25 pmRNSNotice of AGM
31st Aug 201111:46 amRNSHolding(s) in Company
26th Aug 20113:30 pmRNSResult of Open Offer and General Meeting
4th Aug 20119:32 amRNSPosting of Circular
2nd Aug 20117:15 amRNSProposed Placing, Subscription and Open Offer
2nd Aug 20117:00 amRNSFinal Results
29th Jul 201112:10 pmRNSNotice of Results
26th Apr 20117:00 amRNSIssue of Equity
14th Apr 20117:00 amRNSContract with the World Bank
1st Mar 20117:00 amRNSContract Wins and Trading Update
25th Jan 201111:22 amRNSWithdrawal of requisition of General Meeting
12th Jan 201111:01 amRNSHolding(s) in Company
11th Jan 20115:26 pmRNSIssue of Equity
22nd Dec 201012:24 pmRNSResult of General Meeting
22nd Dec 20107:00 amRNSFurther Requisition of General Meeting
16th Dec 20107:00 amRNSHalf Yearly Report
1st Dec 201010:08 amRNSNotice of General Meeting
19th Nov 20107:00 amRNSBoard Appointment
15th Nov 20103:28 pmRNSRequisition of General Meeting
11th Oct 20107:00 amRNSContract Extension with Pfizer
4th Oct 201011:58 amRNSShare Option Schemes
29th Sep 201011:41 amRNSResult of AGM
29th Sep 20107:00 amRNSAGM Statement
10th Sep 20105:00 pmRNSHolding in Company
10th Sep 20103:36 pmRNSHolding(s) in Company
10th Sep 20107:00 amRNSPilot Project Established with NASA
9th Sep 201012:47 pmRNSHolding(s) in Company
6th Sep 20104:14 pmRNSIssue of Equity
24th Aug 20103:16 pmRNSResult of General Meeting
18th Aug 20101:23 pmRNSMarket Update
6th Aug 20106:28 pmRNSPosting of Circular
30th Jul 20104:41 pmRNSHolding(s) in Company
27th Jul 20104:33 pmRNSPosting of Circular convening General Meeting
22nd Jul 201011:53 amRNSHolding(s) in Company
7th Jul 201011:04 amRNSSenior Management Team Appointments
23rd Jun 20107:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.